Citrine Capital’s Revolution Medicines RVMD Stock Holding History

Citrine Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468K	Hold	2,501	–	–	0.17%	36
2026 Q1	$243K	Buy	+2,501	New	+$253K	0.11%	48

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Citrine Capital's RVMD Position: Q2 2026 in Review

Citrine Capital held its Revolution Medicines (RVMD) position steady in Q2 2026 at 2,501 shares worth $468K. The position accounts for 0.17% of the portfolio, ranked #36.

Citrine Capital first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Citrine Capital held 2,501 shares of Revolution Medicines worth $468K as of Q2 2026.
Citrine Capital left its Revolution Medicines share count unchanged in Q2 2026.
Revolution Medicines made up 0.17% of Citrine Capital's portfolio in Q2 2026, its #36 holding.
Citrine Capital first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Citrine Capital's 13F filing for Q2 2026, filed 23 Jul 2026.